Discover Biotech Webinar Pharma FDA & EMA ONCOLife Contact

ONCOLife

BetaBart: New B7-H3 Radio-Theranostic Promises to Broaden Targeted Radiation Across Solid Tumors

ONCOLife

Immunotherapy Boosts Chemotherapy Cutting Recurrence Risk by 50% in St-3 dMMR Colon Cancer

ONCOLife

Nonviral Gene Delivery Platform Offers Promise for Cancer Treatment and Cell Therapy

ONCOLife

New IHC Biomarker Test Predicts Which Gastric Cancer Patients Benefit from Immunotherapy

ONCOLife

Magnetic Nanoparticle-Guided Hyperthermia Opens a New Path for Advanced Solid Tumors

FDA & EMA

FDA Approves Nivolumab-AVD as First Immunotherapy Combination for Hodgkin Lymphoma

ONCOLife

Reengineering CAR-T Cells to Last Longer in the Fight Against Cancer and HIV

ONCOLife

Romiplostim Prevents Chemotherapy Side Effects and Preserves Treatment Intensity

ONCOLife Issues

Featured Articles

FDA Grants Breakthrough Status to WU-CART-007 for Aggressive T-Cell Leukemias and Lymphomas

1 April 2026

FDA has granted Breakthrough Therapy designation to WU-CART-007, an off-the-shelf CAR-T therapy for relapsed or refractory T-ALL and T-LL, two aggressive T-cell cancers with poor outcomes. In a phase 1 study, the therapy achieved a 91% overall response rate an...

Trending Articles

TRBC2-Specific ADC Shows Robust Efficacy in T-Cell Lymphomas and Leukemias

Engineered Oncolytic Virus Reprograms Immunity and Extends Survival in Brain Cancer

ONCOLife

20 December 2025

FDA Approves First Subcutaneous Amivantamab Plus Lazertinib for EGFR+ Lung Cancer

FDA & EMA

18 December 2025

Platinum-Free PADCEV Plus Pembrolizumab Improves Survival in MI Bladder Cancer

Clinical Trials

18 December 2025

Artificial Intelligence Detects Pancreatic Cancer More Accurately Than Radiologists

AI

12 December 2025

FDA Approves T-DXd Plus Pertuzumab as a First-Line Standard in HER2+ Breast Cancer

Less Toxic, More Effective: RW Evidence Supports Reduced Immunotherapy Dose in Melanoma

Clinical Trials

14 December 2025

Teclistamab plus Daratumumab Achieves an 83% Risk Reduction in R/R Multiple Myeloma

Clinical Trials

10 December 2025

FDA Approves AKEEGA for BRCA2+ Prostate Cancer as the First Precision Therapy

FDA & EMA

12 December 2025

GSK’s ADC Risvutatug Rezetecan Earns FDA Orphan Drug Status for Small Cell Lung Cancer

FDA & EMA

10 December 2025

Ribociclib Maintains Long-Term Disease Control in HR+ HER2 Metastatic Breast Cancer

Preoperative Radiation May Improve Immune Response in HR+ HER2- Breast Cancer

Clinical Trials

11 December 2025

Tucatinib Combination Cuts Progression Risk by 36% in HER2+ Metastatic Breast Cancer

Clinical Trials

10 December 2025

Giredestrant Cuts Risk of Invasive Recurrence by 30% in Early ER+ Breast Cancer

Clinical Trials

10 December 2025

CAR T Anito cel Delivers Deep, Durable Responses in R&R Multiple Myeloma

ONCOLife

9 December 2025